WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, announced today that results of new research on several of its next-generation tetracycline antibiotics will be presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentations will include late-breaking results of a Phase 2 clinical trial of the company’s lead agent, eravacycline (TP-434), and chemical and biological evaluations of other novel tetracyclines in the company’s portfolio. ICAAC will be held September 9-12, 2012, in San Francisco, CA.
